Assessment of Frequency and Reporting of Changes in Cancer Trial Design After Initiation of Patient Accrual-Reference-Cited by-同舟云学术

Assessment of Frequency and Reporting of Changes in Cancer Trial Design After Initiation of Patient Accrual

Published:2019-01-01 Issue:1 Volume:5 Page:107
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Shepshelovich Daniel¹²,Tibau Ariadna³,Molto Consolación³,Goldvaser Hadar¹⁴,Ocana Alberto⁵⁶,Šeruga Bostjan⁷,Amir Eitan¹⁸

Affiliation:

1. Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

2. Department of Internal Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

3. Oncology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain

4. Department of Oncology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

5. Research Unit, Translational Oncology Laboratory, Regional Center for Biomedical Research (CRIB), Albacete University Hospital, Albacete, Spain

6. Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Castilla–La Mancha University, Albacete, Spain

7. Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia

8. Department of Medicine, University of Toronto, Toronto, Ontario, Canada

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference6 articles.

1. From protocols to publications: a study in selective reporting of outcomes in randomized trials in oncology.;Raghav;J Clin Oncol,2015

2. Characteristics of interim publications of randomized clinical trials and comparison with final publications.;Woloshin;JAMA,2018

3. Comparison of primary endpoints between publications, registries, and protocols of phase III cancer clinical trials.;Liang;Oncotarget,2017

4. CONSORT statement, 6b: changes to outcomes. http://www.consort-statement.org/checklists/view/32--consort-2010/81-changes-to-outcomes. Accessed June 12, 2018.

5. US Food and Drug Administration. Hematology/oncology (cancer) approvals & safety notifications. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm. Updated October 16, 2018. Accessed October 28, 2018.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in primary outcome and sample size measures after initiation of accrual among trials supporting approval of drugs for hematological malignancies by the US food and drug administration;Leukemia & Lymphoma;2020-05-23

2. ‘The same old story’: thoughts on authorized doses of anticancer drugs;Therapeutic Advances in Medical Oncology;2020-01

3. Assessment of frequency and reporting of design changes among clinical drug trials published in influential medical journals;European Journal of Internal Medicine;2020-01